Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SeqMan NGen and SeqMan Pro Now Available in Illumina’s BaseSpace Apps

Published: Wednesday, November 13, 2013
Last Updated: Tuesday, November 12, 2013
Bookmark and Share
New Apps make sequence assembly and analysis workflows available to Company’s customers quickly.

DNASTAR® has announced that it has added the SeqMan NGen and SeqMan Pro applications to Illumina’s BaseSpace Apps, Illumina’s dedicated applications store and informatics community dedicated to advancing genomic analysis.

Illumina BaseSpace users are now able to license DNASTAR’s software for one, two, or three days to perform de novo or reference-guided sequence assembly and analysis of a multitude of data sets.

SeqMan NGen supports reference-guided human exome alignment and SNP calling as well as templated or de novo bacterial genome assembly and many other assembly and alignment workflows through its flexible interface and algorithms.

SeqMan Pro enables strong visualization, analysis, and filtering of data for one or multiple projects using sequence data from Illumina’s BaseSpace environment.

Tom Schwei, Vice President and General Manager of DNASTAR, commented, “One year ago, we were pleased to participate in Illumina’s BaseSpace beta launch. Since then, we’ve seen a large number of scientists try our initial BaseSpace App, which supported de novo bacterial genome assembly. In May 2013, we introduced the DNASTAR Cloud, supplementing our traditional desktop computer software by making all DNASTAR software available on the Amazon cloud. A natural next step was to broaden our offering on Illumina’s BaseSpace to support a much wider range of workflows used by Illumina customers every day. Our new SeqMan NGen and SeqMan Pro BaseSpace Apps make all of our sequence assembly and analysis workflows available to Illumina customers quickly and efficiently. We are excited to continue our relationship with Illumina and their customers and we look forward to fast adoption of our new software offering. Our mission throughout our company history has been to provide the tools required by life scientists where and when they need them. By substantially broadening our software offering on BaseSpace, we are further advancing that mission today.”

Informatics solutions available through BaseSpace Apps allow customers to utilize the tools from a growing community of academic, commercial, and open source providers.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Wellcome Trust Sanger Institute Adopts DNASTAR Lasergene Software
Wellcome Trust Sanger Institute and DNASTAR have entered into a multi-year software license agreement.
Thursday, December 05, 2013
DMNB Adopts DNASTAR Lasergene Software
New Lasergene software site license agreement for genome sequence assembly and analysis.
Thursday, September 05, 2013
DNASTAR Awarded Antibody Engineering SBIR Grant
NIH awarded grant to build antibody engineering software.
Tuesday, May 15, 2012
DNASTAR Partners with Ion Torrent
Ion Torrent offers DNASTAR’s sequence assembly and analysis software products to the customers through the Ion Torrent on-line web store in the collaboration.
Wednesday, February 16, 2011
DNASTAR Joins BioIT Alliance
BioIT Alliance announces the expansion of the BioIT Alliance program to include DNASTAR.
Thursday, January 28, 2010
DNASTAR and the University of Iowa Sign Lasergene Site License Agreement
Researchers on the University of Iowa campus have gained unlimited access and use of the software for their sequence analysis projects.
Wednesday, January 06, 2010
Wageningen University and DNASTAR Extend Lasergene Site License Agreement
Under the terms of the site license, researchers will have unlimited use of the software for their sequence analysis projects.
Tuesday, November 24, 2009
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Micro Disease-Detecting Sensor Created
Researchers at McMaster University have created a microscopic disease-detecting sensor that can turn on to detect trace amounts of substances.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!